Zyclara: new strength of imiquimod for actinic keratosis

Zyclara (imiquimod) is a cream for the topical treatment of non-hyperkeratotic and non-hypertrophic actinic keratosis of the face and scalp. It is indicated for use when other topical treatment options are contraindicated or less appropriate.

Zyclara should remain on the skin for approximately 8 hours.
Zyclara should remain on the skin for approximately 8 hours.

PHARMACOLOGY

Imiquimod is an immune response modifier that has been shown to increase systemic levels of interferon alfa and other cytokines following topical application.1

CLINICAL STUDIES

The safety and efficacy of imiquimod were evaluated in two double-blind, placebo-controlled studies involving 319 patients with five to 20 typical visible or palpable AK lesions of more than 25cm2 on the face or scalp.2

Up to two sachets of imiquimod 3.75% cream or a matching vehicle cream were applied to the entire face or balding scalp once daily for two 2-week treatment cycles separated by a 2-week treatment-free period.2

Overall, 35.6% of patients treated with imiquimod 3.75% cream had complete clearance eight weeks post-treatment compared with 6.3% of those treated with placebo.2

The most commonly reported side-effects are application site reactions, including erythema, scabbing, exfoliation and dryness.1

References:

1.    Zyclara Summary of Product Characteristics, August 2012.
2.    Swanson N et al. J Am Acad Dermatol 2010; 62: 582–90.

View Zyclara drug record

Further information: Meda Pharmaceuticals Ltd

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more